News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
674,509 Results
Type
Article (38548)
Company Profile (191)
Press Release (635770)
Section
Business (202847)
Career Advice (1957)
Deals (35335)
Drug Delivery (74)
Drug Development (80448)
Employer Resources (167)
FDA (15929)
Job Trends (14751)
News (342692)
Policy (32378)
Tag
Academia (2524)
Africa (708)
Allergies (37)
Alliances (48858)
Alzheimer's disease (1093)
Antibody-drug conjugate (ADC) (43)
Approvals (15872)
Arizona (159)
Artificial intelligence (48)
Asia (36566)
Australia (5944)
Bankruptcy (350)
Best Places to Work (11171)
Biosimilars (55)
C2C Services and Suppliers (78801)
California (820)
Canada (641)
Cancer (176)
Career advice (1635)
CAR-T (32)
Cell therapy (65)
China (48)
Clinical research (62577)
Collaboration (56)
Colorado (33)
Compensation (30)
COVID-19 (2452)
Cystic fibrosis (69)
Diabetes (32)
Diagnostics (5888)
Diversity, equity & inclusion (44)
Drug pricing (47)
Earnings (82761)
Employer resources (141)
Europe (78083)
Events (106900)
FDA (15973)
Florida (106)
Funding (37)
Gene therapy (52)
GLP-1 (465)
Government (4272)
Healthcare (18526)
Hotbed/Location (481045)
Idaho (55)
Illinois (194)
Indiana (105)
Infectious disease (2465)
Inflammatory bowel disease (83)
Interviews (305)
IPO (16116)
Job creations (3616)
Job search strategy (1410)
Kansas (90)
Layoffs (372)
Legal (7814)
Liver cancer (51)
Lung cancer (37)
Maine (47)
Management (53)
Manufacturing (45)
Maryland (251)
Massachusetts (450)
Medical device (12944)
Medtech (12947)
Mergers & acquisitions (18920)
Metabolic disorders (154)
Neuroscience (1170)
New Jersey (62)
New York (83)
NextGen Class of 2024 (6445)
Non-profit (4441)
North Carolina (158)
Obesity (101)
Opinion (160)
Parkinson's disease (29)
Patents (33)
Peanut (33)
Pennsylvania (55)
People (55519)
Phase I (19398)
Phase II (27566)
Phase III (20607)
Policy (33)
Postmarket research (2544)
Preclinical (8270)
Rare diseases (89)
Real estate (5877)
Recruiting (63)
Regulatory (21011)
Reports (32)
Research institute (2297)
Resumes & cover letters (343)
South America (1085)
Startups (3547)
Texas (87)
United States (3002)
Vaccines (408)
Washington State (113)
Weight loss (96)
Date
Today (66)
Last 7 days (496)
Last 30 days (1912)
Last 365 days (38258)
2024 (21594)
2023 (40074)
2022 (51173)
2021 (55714)
2020 (54096)
2019 (46545)
2018 (35021)
2017 (32111)
2016 (31480)
2015 (37554)
2014 (31318)
2013 (26346)
2012 (28570)
2011 (29263)
2010 (27328)
674,509 Results for "chromadex inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
ChromaDex to Join Russell 2000® Index
ChromaDex Corp., the global authority on nicotinamide adenine dinucleotide research with a focus on healthy aging, announced its inclusion in the Russell 2000® Index as part of the annual reconstitution of the Russell stock indexes.
July 1, 2024
·
6 min read
Biotech Beach
ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow on Tuesday, June 11, 2024
ChromaDex Corp. announced today that it will be participating in Renmark Financial Communications Inc.’s live Virtual Non-Deal Roadshow Series to discuss its latest investor presentation on Tuesday, June 11, 2024, at 2:00pm PST.
June 4, 2024
·
2 min read
Business
ChromaDex Corporation Reports First Quarter 2024 Financial Results
ChromaDex Corp. announced financial results for the first quarter of 2024.
May 8, 2024
·
13 min read
Biotech Beach
ChromaDex to Launch Niagen+, the First-Of-Its-Kind Pharmaceutical-Grade Intravenous and Injectable Niagen® (Patented Nicotinamide Riboside Chloride or NRC)
ChromaDex Corp., the global authority on nicotinamide adenine dinucleotide research and its application to healthy aging, unveils Niagen+, the first-of-its-kind pharmaceutical-grade Niagen®.
June 13, 2024
·
9 min read
Biotech Beach
ChromaDex to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024
ChromaDex Corp. today announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Brianna Gerber, will be participating in the Lytham Partners Spring 2024 Investor Conference, taking place virtually on Thursday, May 30, 2024.
May 23, 2024
·
2 min read
Business
ChromaDex to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024
ChromaDex Corp. announced that it will hold a conference call on Wednesday, May 8, 2024 at 4:30 p.m. ET to discuss its financial results for the first quarter, which ended March 31, 2024.
April 24, 2024
·
4 min read
FDA
ChromaDex Receives Exclusive U.S. FDA Orphan Drug Designation (ODD) and Rare Pediatric (RPD) Disease Designation for Nicotinamide Riboside Chloride (NRC) for the Treatment of Ataxia Telangiectasia (AT)
ChromaDex Corp. today announced that the U.S. Food & Drug Administration (FDA) granted Orphan Drug Designation (ODD) and Rare Pediatric Disease (RPD) Designation for NRC, the company’s product candidate for the treatment of Ataxia Telangiectasia (AT).
June 7, 2024
·
8 min read
Biotech Beach
ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow on Monday, February 12, 2024
ChromaDex Corp. announced today that it will be participating in Renmark Financial Communications Inc.’s live Virtual Non-Deal Roadshow Series to discuss its latest investor presentation on Monday, February 12, 2024, at 11:00 AM PST.
February 5, 2024
·
2 min read
Business
ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2023 Results
ChromaDex Corp. announced fourth quarter and fiscal year 2023 financial results. Fourth Quarter 2023 and Recent Highlights Total net sales of $21.2 million, with $17.6 million from Tru Niagen®, up 1% and 9%, respectively, from the prior year quarter.
March 6, 2024
·
16 min read
Business
ChromaDex to Report Fourth Quarter 2023 Financial Results on Wednesday, March 6, 2024
ChromaDex Corp. announced that it will hold a conference call on Wednesday, March 6, 2024 at 4:30 p.m. ET to discuss its financial results for the fourth quarter, which ended December 31, 2023.
February 21, 2024
·
4 min read
1 of 67,451
Next
